Financial Performance - Revenue for the year ended December 31, 2025, was HKD 796,041,000, representing an increase of 11.2% from HKD 715,682,000 in 2024[4] - Gross profit for the same period was HKD 324,332,000, up 13.2% from HKD 286,593,000 in 2024[4] - Net profit for the year decreased by 32.9% to HKD 56,633,000 from HKD 84,359,000 in 2024[4] - Total comprehensive income for the year was HKD 197,456,000, significantly higher than HKD 22,354,000 in 2024[6] - Basic earnings per share for 2025 was HKD 17.028, down from HKD 24.929 in 2024[6] - The company reported a net profit of HKD 56,633,000 for the year ended December 31, 2025, compared to HKD 84,359,000 in 2024, indicating a decrease of 32.9%[19] - The company's profit before tax for 2025 was HKD 102,438,000, a decrease of 19% from HKD 126,466,000 in 2024[31] - The income tax expense for 2025 was HKD 45,805,000, compared to HKD 42,107,000 in 2024, reflecting an increase of 6.4%[31] - Basic earnings per share for 2025 were HKD 17.028, down 31.5% from HKD 24.929 in 2024[33] - Diluted earnings per share for 2025 were HKD 17.026, a decrease of 31.5% from HKD 24.915 in 2024[34] Assets and Liabilities - Non-current assets increased to HKD 1,175,583,000 from HKD 885,835,000 in 2024, driven by higher property, plant, and equipment[7] - Total assets reached HKD 1,952,235,000, compared to HKD 1,599,435,000 in 2024[8] - Total liabilities increased to HKD 667,778,000 from HKD 473,721,000 in 2024, primarily due to higher lease liabilities[8] - The company reported a significant increase in goodwill, rising to HKD 369,870,000 from HKD 253,407,000 in 2024[7] - Cash and cash equivalents at year-end were HKD 695,541,000, compared to HKD 653,232,000 in 2024, indicating improved liquidity[7] Revenue Breakdown - The revenue from vision correction services was HKD 788,731,000 in 2025, up from HKD 710,875,000 in 2024, marking a growth of 10.9%[20] - The revenue from Germany in 2025 was HKD 426,788,000, up from HKD 385,195,000 in 2024, indicating a growth of 10.8%[21] - The revenue from external customers in the UK for 2025 was HKD 134,534,000, an increase from HKD 113,381,000 in 2024, showing a growth of 18.6%[21] - The revenue from training services in Denmark for 2025 was HKD 76,752,000, an increase from HKD 71,638,000 in 2024, reflecting a growth of 7.4%[21] - Revenue from the presbyopia treatment segment reached HKD 448.8 million, up 14.8%, while the Presbyond division generated HKD 33.2 million, an increase of 26.1%[46] - The group’s presbyopia treatment segment accounted for 61.2% of total revenue, up from 58.8% the previous year[46] Expenses - The total sales cost for the year ended December 31, 2025, was HKD 471,709,000, compared to HKD 429,089,000 in 2024, reflecting a rise of 9.9%[19] - The company’s total employee benefit expenses amounted to HKD 205,522,000 for the year ended December 31, 2025, compared to HKD 190,622,000 in 2024, indicating an increase of 7.8%[19] - Employee benefits expenses rose to HKD 266,647,000 in 2025, compared to HKD 246,932,000 in 2024, reflecting an increase of 7.9%[27] - The total expenses for the group in 2025 amounted to HKD 681,024,000, up from HKD 625,565,000 in 2024, marking a rise of 8.8%[27] - Sales expenses rose by 19.7% to approximately HKD 96.7 million, representing 12.1% of total revenue, compared to 11.3% last year[68] Financial Position - The group had outstanding borrowings of approximately HKD 300,000 as of December 31, 2025, down from HKD 900,000 in 2024[74] - The group has no long-term borrowings as of December 31, 2025, and continues to monitor its capital based on the debt-to-equity ratio[89] - The maximum credit risk faced by the company in 2025 was HKD 14,461,000, compared to HKD 5,469,000 in 2024[38] - The company recognized a provision for impairment of trade receivables amounting to HKD 830,000 in 2025, up from HKD 731,000 in 2024[38] Acquisitions and Future Plans - The company successfully completed an acquisition in Switzerland in October 2025, contributing HKD 11.8 million to total revenue, and is awaiting shareholder approval for a strategic acquisition in the Netherlands[47] - The total consideration for the acquisition of assets in Switzerland was CHF 12,010,000, equivalent to approximately HKD 117,029,043[80] - The company is planning a significant acquisition in the Netherlands, which is classified as a very substantial acquisition under the listing rules, requiring shareholder approval by June 30, 2026[99] - The company aims for a compound annual growth rate of 10% for revenue and 10% for EBITDA by the fiscal year ending December 31, 2028[57] Governance and Compliance - The group has complied with the corporate governance code, with a noted deviation regarding the roles of the Chairman and CEO being held by the same individual[85] - The audit committee, composed of three independent non-executive directors, reviewed the consolidated annual performance and confirmed compliance with relevant accounting standards and regulations[93] - The company has confirmed compliance with the standard code of conduct for securities trading by all directors for the fiscal year ending December 31, 2025[88] Shareholder Information - The company proposed a final dividend of HKD 0.0126 per share, amounting to approximately HKD 4,041,000, pending shareholder approval[96] - The company repurchased 5,211,000 shares, representing about 1.57% of the total issued shares as of the 2024 annual general meeting, at a total cost of HKD 18,331,120[94] - The net proceeds from the global offering, totaling approximately HKD 660.66 million, will be allocated for establishing clinics in major Chinese cities, potential acquisitions of clinic groups in Europe, increased marketing efforts, and general corporate purposes[91]
德视佳(01846) - 2025 - 年度业绩